Nature Publishing Group, publisher of Nature, and other science journals and reference works NATURE.COM NATURE NEWS NATUREJOBS NATUREEVENTS ABOUT NPG
Help Nature.com site index  
Spinal Cord
SEARCH     advanced search my account e-alerts subscribe register
Journal home
Advance online publication
Current issue
Archive
Press releases
For authors
For referees
Contact editorial office
About the journal
For librarians
Subscribe
Advertising
naturereprints
Contact NPG
Customer services
Site features
NPG Subject areas
Access material from all our publications in your subject area:
Biotechnology Biotechnology
Cancer Cancer
Chemistry Chemistry
Dentistry Dentistry
Development Development
Drug Discovery Drug Discovery
Earth Sciences Earth Sciences
Evolution & Ecology Evolution & Ecology
Genetics Genetics
Immunology Immunology
Materials Materials Science
Medical Research Medical Research
Microbiology Microbiology
Molecular Cell Biology Molecular Cell Biology
Neuroscience Neuroscience
Pharmacology Pharmacology
Physics Physics
Browse all publications
 
January 2002, Volume 40, Number 1, Pages 48-49
Table of contents    Previous  Article  Next   [PDF]
Letter
Clopidogrel and recurrent severe haematuria in a patient with paraplegia
S Vaidyanathan1, B M Soni1, G Singh1, P L Hughes2 and P Mansour3

1Regional Spinal Injuries Centre, District General Hospital, Southport PR8 6PN, UK

2Department of Radiology, District General Hospital, Southport PR8 6PN, UK

3Department of Cellular Pathology, District General Hospital, Southport PR8 6PN, UK

Individuals with spinal cord injury (SCI) are more likely to die from heart disease, and at an earlier age, than the able-bodied population, and a clustering of risk factors associated with ischaemic heart disease (including hyperlipidemia, hypertension and diabetes mellitus) has been demonstrated in them.1 It is therefore likely that some people with SCI will be taking anti-platelet drugs, including glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors such as clopidogrel.

Clopidogrel inhibits platelet aggregation by selectively blocking the binding of adenosine diphosphate (ADP) to its platelet receptor, and subsequent ADP-mediated activation of the GP IIb/IIIa complex. Because it irreversibly modifies the platelet ADP receptor, platelets exposed to clopidogrel are affected for the remainder of their life span. Repeated doses of 75 mg per day of clopidogrel produce substantial inhibition of ADP-induced platelet aggregation from the first day. After stopping clopidogrel, platelet aggregation and the bleeding times gradually return to baseline values, usually within 5 days. The overall incidence of bleeding in the patients taking clopidogrel is 9.3%; gastrointestinal bleeding occurs in 2.0%, and 0.7% need hospitalisation.2

We report a patient with paraplegia, who was taking clopidogrel and who developed severe recurrent haematuria following cystoscopy, removal of bladder stones and bladder biopsy.

Case report

A 56-year-old male developed paraplegia following aortic aneurysm repair. He also suffered from transient ischaemic attacks, for which he was prescribed aspirin 75 mg and clopidogrel 75 mg. Bladder drainage was by a long-term indwelling urethral catheter, and he subsequently developed bladder stones. Cystoscopy revealed highly congested bladder mucosa. The stones were flushed out and a cold cup biopsy of bladder mucosa was performed, the biopsy site being fulgurated with diathermy. Urine was noted to be clear at the end of the procedure. About 9 h later, the patient developed haematuria, which became progressively severe over the next few days, requiring continuous bladder irrigation through a 22 Fr. three-way Foley catheter.

Histology of the bladder biopsy showed moderate chronic inflammation with an acute inflammatory component. Although the biopsy section showed presence of blood vessels, it did not contain any blood vessel of sufficient size to explain such marked post-biopsy bleeding (Figure 1). Clopidogrel was stopped and haematuria subsided over the next 5-7 days, following which clopidogrel was then recommenced. Seven weeks later, he again developed severe haematuria. Clopidogrel was discontinued once again and he was instead prescribed dalteparin sodium (2500 units subcutaneously once a day). Haematuria subsided gradually during the course of next week.

On an abdominal computerised tomography (CT) scan and ultrasound examination, the right kidney was normal while the left contained a parapelvic cyst measuring 4 cm in diameter, with some calcification but no irregular thickening of the cyst wall. No other lesion was demonstrated that could account for the haematuria.

He was discharged home on aspirin and dalteparin sodium. He now takes warfarin and wears a penile sheath for drainage of his neuropathic bladder; he is doing very well. Follow-up CT scan of the kidneys showed no subsequent changes in size of the left parapelvic cyst (which appeared benign), no alteration in the associated calcification and no evidence of any related soft tissue abnormality.

Discussion

As this case illustrates, significant bleeding can occur in the patients who continue to take anti-platelet drugs during invasive operative procedures. For this reason, Zhu and associates from Denmark3 recommended stopping aspirin 1 week prior to all invasive urological procedures. On the other hand, patients who stop taking such drugs risk developing thrombotic or embolic phenomena. In our case, we were indeed concerned that our patient might develop just such a major ischaemic episode if he were to stop taking his anti-platelet drugs before the procedure, and we therefore did not advise him to do so. Such risks are not merely theoretical: when anticoagulant therapy was stopped prior to dental surgery, five patients out of 526 (0.95%) suffered serious embolic complications, and four of these died.4 Furthermore, Ardekian and associates5 showed that aspirin therapy can safely be continued during oral surgery, as local haemostasis is sufficient to control bleeding. Opinion and practice vary widely between radiologists and urologists in the United Kingdom with regard to stopping aspirin and warfarin before prostate biopsy: 52% of radiologists compared with 27% of urologists advocate stopping such drugs before the biopsy.6

Thus the potential complication of bleeding after an invasive urological procedure must be balanced against the risk of developing a thrombotic episode when anti-platelet drugs such as clopidogrel are discontinued, particularly in those (including SCI patients) who are already at high risk of developing heart disease. It may be that the chronically inflamed neuropathic bladder is somwhat more prone to post-biopsy haemorrhage than the healthy bladder. As is often the case in medicine, a therapeutic tightrope must be walked, and in the end each case must be decided on its own merits.

Acknowledgements

Our gratitude to Pannone & Partners, Solicitors, (cathy.leech@pannone.co.uk), 123 Deansgate, Manchester, M3 2BU, UK, for kindly sponsoring the printing of the colour illustration. Pannone & Partners (www.pannone.com) are delighted to be able to support this publication in Spinal Cord.

References

1 Bauman WA, Kahn NN, Grimm DR, Spungen AM. Risk factors for atherogenesis and cardiovascular autonomic function in persons with spinal cord injury. Spinal Cord 1999; 37: 601-616. MEDLINE

2 The Association of the British Pharmaceutical Industry (ABPI). Compendium of Data Sheets and Summaries of Product Characteristics. 1999-2000; pp. 252-254.

3 Zhu JP, Davidsen MB, Meyhoff HH. Aspirin, a silent, risk factor in urology. Scand J Urol Nephrol 1995; 29: 369-374. MEDLINE

4 Wahl MJ et al. Myths of dental surgery in patients receiving anticoagulant therapy. J Am Dent Assoc 2000; 131: 77-81. MEDLINE

5 Ardekian L et al. Does low-dose aspirin therapy complicate oral surgical procedures? J Am Dent Assoc 2000; 131: 331-335. MEDLINE

6 Connor SE, Wingate JP. Management of patients treated with aspirin or warfarin and evaluation of haemostasis prior to prostatic biopsy: a survey of current practice amongst radiologists and urologists. Clin Radiol 1999; 54: 598-603. MEDLINE

Figures

Figure 1 Photomicrograph of bladder biopsy showing moderate chronic inflammation with a minor acute inflammatory component. Two or three vessels of moderate size are included. The urothelium is largely denuded in this section

January 2002, Volume 40, Number 1, Pages 48-49
Table of contents    Previous  Article  Next    [PDF]
Privacy Policy © 2002 Nature Publishing Group